Receptor tyrosine kinase inhibition, hypertension, and proteinuria: Is endothelin the smoking gun?

Hypertension

Volumn 56, Issue 4, 2010, Pages 575-577

  Dhaun, Neeraj ^a   Webb, David J ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; ATRASENTAN; ENDOTHELIN 1; NITRIC OXIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; RISK FACTOR;

BLOOD PRESSURE; CARCINOMA, RENAL CELL; ENDOTHELIN-1; GASTROINTESTINAL STROMAL TUMORS; HEART RATE; HUMANS; HYPERTENSION; INDOLES; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; PROTEINURIA; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RENIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957233990     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.155762     Document Type: Note

References (15)

1. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359-1364.
2. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52. (Pubitemid 38821812)
3. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis. 2002;5:237-256. (Pubitemid 36875123)
4. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs. 2009;20:81-82.
5. Kappers MHW, van Esch JHM, Sluiter W, Sleijfer S, Danser AHJ, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56:675-681.
6. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension. 2008;52:452-459.
7. Banfor PN, Franklin PA, Segreti JA, Widomski DL, Davidsen SK, Albert DH, Cox BF, Fryer RM, Gintant GA. ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol. 2009;53:173-178.
8. Knowles J, Loizidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Current Vasc Pharmacol. 2005;3:309-314. (Pubitemid 41264282)
9. Gu JW, Manning RD Jr, Young E, Shparago M, Sartin B, Bailey AP. Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats. Am J Physiol. 2009; 297:142-148.
10. Kohan DE. Biology of endothelin receptors in the collecting duct. Kidney Int. 2009;76:481-486.
11. Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356:1966-1978.
12. Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant. 2010;25:1001-1003.
13. Bollee G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noel LH, Knebelmann B. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24:682-685.
14. Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010;5:477-483.
15. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Rakoczy PE, Gilbert RE. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci. 2007; 104:14448-14453. (Pubitemid 350003281)